Exome Sequencing for Isolated Congenital Hearing Loss: A Cost-Effectiveness Analysis

Abstract

Objectives/Hypothesis: To assess the relative cost-effectiveness of exome sequencing for isolated congenital deafness compared with standard care. Study Design: Incremental cost-effectiveness and cost-benefit analyses were undertaken from the perspective of the Australian healthcare system using an 18-year time horizon. Methods: A decision tree was used to model the costs and outcomes associated with exome sequencing and standard care for infants presenting with isolated congenital deafness. Results: Exome sequencing resulted in an incremental cost of AU$1,000 per child and an additional 30 diagnoses per 100 children tested. The incremental cost-effectiveness ratio was AU$3,333 per a..